The pathobiology of diabetes mellitus: Implications for surgeons

Journal of the American College of Surgeons

Volumn 183, Issue 3, 1996, Pages 271-289

  Kamal, Khurram ^a   Powell, Richard J ^a   Sumpio, Bauer E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIACYLGLYCEROL; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; POLYOL; PROTEIN KINASE C;

ATHEROSCLEROSIS; AUTONOMIC NEUROPATHY; BASEMENT MEMBRANE; CIGARETTE SMOKING; CLAUDICATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DYSLIPIDEMIA; ENDOTHELIUM; FOOT ULCER; GLYCOSYLATION; HEMODYNAMICS; HYPERGLYCEMIA; HYPERTENSION; INFECTION; PATHOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; ULCER HEALING; VASCULAR DISEASE; WOUND HEALING;

ARTERIOSCLEROSIS; BASEMENT MEMBRANE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETIC FOOT; DIGLYCERIDES; ENDOTHELIUM, VASCULAR; GLYCOSYLATION; HUMANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PROTEIN KINASE C; SURGICAL PROCEDURES, OPERATIVE; WOUND HEALING;

EID: 0029756590     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (262)

1. Harris, M., Hadden, W. C., Knowles, W. C., and Bennett, P. H. Prevalence of diabetes and impaired glucose tolerance and glucose levels in the US population aged 20-40 years. Diabetes, 1987, 36: 523-534.
2. Nathan, D. M. Long term complications of diabetes mellitus. N. Engl. J. Med., 1993, 328: 1676-1684.
3. Boulton, A. J. M. The diabetic foot. Med. Clin. North Am., 1988, 72: 1513-1530.
4. Lopes-Virella, M. F. Peripheral vascular disease. In: Diabetes Annual. Edited by S. M. Marshall, and P. D. Home, Pp. 365-387. 8th ed. Amsterdam: Elsevier Science BV, 1994.
5. Gibbons, G. W. Vascular surgery of the diabetic lower extremity. In: The High Risk Foot in Diabetes Mellitus. Edited by R. G. Frykberg. Pp. 273-296. New York: Churchill Livingstone, 1991.
6. Gensler, S. W., Haimovici, H., Hoffer, P., and others. Study of vascular lesion in diabetic and non diabetic patients. Arch. Surg., 1965, 91: 617-622.
7. Flynn, M. D., and Tooke, J. E. Aetiology of diabetic foot ulceration: a role for the microcirculation. Diabet. Med., 1992, 9: 320-329.
8. Strandness, D. E., Priest, R. E., Gibbon, R. E., and others. Combined clinical and pathological study of diabetic and nondiabetic peripheral artery disease. Diabetes, 1961, 13: 366-372.
9. Brand, F. N., Abbot, W., and Kennel, W. B. Diabetes, intermittent claudication and risk of cardiovascular events. The Framingham Study. Diabetes, 1989, 38: 504-509.
10. Osmundson, P. J., O'Fallon, W. M., Zimmerman, B. R., and others. Course of peripheral occlusive disease in diabetes. Vascular laboratory assessment. Diabetes Care, 1990, 11: 143-152.
11. Edmonds, M. E., Blundell, M. P., Morris, H. E., and others. Improved survival of diabetic foot: the role of a specialized foot clinic. Q. J. Med., 1986, 232: 736-771.
12. Edmonds, M. E., and Foster, A. V. M. Classification and management of neuropathic and neuroischemic ulcer. In: The Foot in Diabetes. Edited by A. J. M. Boulton, H. Connor, and R. R. Cavanagh. Pp. 109-20. 2nd ed. Chichester, England: John Wiley & Sons Ltd., 1994.
13. Grenfell, A., and Watkins, P. J. Clinical diabetic nephropathy: natural history and complications. Clin. Endocrinol. Metab., 1986, 15: 783-805.
14. Fernando, D. J. S., Hutchinson, A., Veves, A., and others. Risk factors for non-ischemic foot ulceration in diabetic nephropathy. Diabet. Med., 1991, 8: 223-225.
15. Pecoraro, R. E., Ahroni, J. H., Boyko, E. J., and Stensel, V. L. Chronology and determinants of tissue repair in diabetic lower extremity. Diabetes, 1991, 40: 1305-1313.
16. Tooke, J. E. The microcirculation in diabetes. Diabet. Med., 1987, 4: 189-196.
17. Archer, A. G., Robert, V. C., and Watkin, P. J. Blood flow pattern in painful diabetic neuropathy. Diabetologia, 1984, 27: 563-567.
18. Thomson, F., Veves, A., Ashe, H., and others. A team approach to diabetic foot care: the Manchester experience. The Foot., 1991, 1: 75-82.
19. Boulton, A. J. M., Kubrusly, D. B., Bowker, J. H., and others. Impaired vibratory perception and diabetic foot ulceration. Diabet. Med., 1986, 3: 335-337.
20. Edmonds, M. E. Experience in a multi-disciplinary diabetic foot clinic. In: The Foot in Diabetes. Edited by H. Connor, A. J. M. Boulton, and J. D. Wards. Pp. 121-133. 1st ed. Chichester, England: John Wiley & Sons Ltd., 1987.
21. Boulton, A. J. M., Bett, R. P., Frank, C. I., and others. Abnormalities of foot pressure in early diabetic neuropathy. Diabet. Med., 1987, 4: 225-228.
22. Delbridge, L., Ctercteko, G., Fowler, C., and others. The aetiology of diabetic neuropathic foot ulceration. Br. J. Surg., 1985, 72: 1-6.
23. Delbridge, L., Perry, P., Marr, S., and others. Limited joint mobility in the diabetic foot: relationship to neuropathic ulceration. Diabet. Med., 1988, 5: 333-337.
24. Boulton, A. J. M. Peripheral neuropathy and diabetic foot The Foot., 1992, 2: 67-72.
25. Bridges, R. J. M., and Deitch, E. A. Diabetic foot infections: Pathophysiology and treatment. Surg. Clin. North Am., 1994, 74: 537-555.
26. Wheat, L. J., Allen, S. D., Henry, M., and others. Diabetic foot infections: bacteriologic analysis. Arch. Intern. Med., 1986, 146: 1935-1940.
27. Ramani, A., Kundaje, G. N., and Nayak, M. N. Hemorheologic approach in the treatment of diabetic foot ulcers. Angiology, 1993, 44: 623-626.
28. Knighton, D. R., Fiegel, V. D., Austin, L. L., and others. Classification and treatment of chronic non healing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann. Surg., 1986, 204: 322-330.
29. Richard, J.-L., Parer-Richard, C., Clovet, S., and others. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcers of the foot. Diabetes Care, 1995, 18: 64-69.
30. Malone, J. M., Synder, M., Anderson, G., and others. Prevention of amputation by diabetic education. Am. J. Surg., 1986, 158: 520-523.
31. Young, M. J., Boulton, A. J. M., Mcleod, A. F., and others. A multicentre study of the prevalence of diabetic neuropathy in UK hospital clinic population. Diabetologia, 1993, 36: 150-154.
32. Greene, D. A., Lattimer, S. A., and Sima, A. A. F. Pathogenesis and prevention of diabetic neuropathy. Diabetes Metab. Rev., 1988, 4: 201-221.
33. Tomlinson, D. R. Polyols and myo-inositol in diabetic neuropathy - mouse and men. Mayo Clin. Proc., 1989, 64: 1030-1035.
34. Dyck, P. J., Zimmerman, B. R., Vilan, T. H., and others. Nerve glucose, fructose, myo-inositol, sorbitol and fiber degeneration in diabetic neuropathy. N. Engl. J. Med., 1988, 319: 542-548.
35. Greene, D. A. Effect of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy. J. Diabetes Complications, 1992, 6: 35-38.
36. Sima, A. A. F., Bril, V., Nathaniel, V., and others. Regeneration and repair of myelinated fibers in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N. Engl. J. Med., 1988, 319: 548-555.
37. Tefaye, F., Malik, R., and Ward, J. D. Vascular factors in diabetic neuropathy. Diabetologia, 1994, 37: 847-854.
38. Zioupos, P., Barbenel, J. C., Lowe, G. D., and MacRury, S. Foot microcirculation and blood rheology in diabetes. J. Biomed. Eng., 1993, 15: 155-158.
39. Britland, S. T., Young, R. J., Sharma, A. K., and Clarke, B. F. Relationship of endoneurial capillary abnormalities to type and severity of diabetic polyneuropathy. Diabetes, 1990, 39: 909-913.
40. Tesfaye, S., Harris, N., Jakubowski, J., and others. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia, 1993, 36: 1266-1274.
41. Nerwick, P. J., Wilson, A. J., Jakubowski, J., and Boulton, A. J. M. Sural nerve oxygen tension in diabetes. B. M. J., 1986, 293: 1053-1054,
42. Hellweg, R., and Hartung, H. D. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J. Neurosci. Res., 1990, 26: 258-267.
43. Faradji, V., and Sotelo, J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol. Scand., 1990, 81: 402-406.
44. Molenaar, D. M., Palumbo, P. J., Wilson, W. R., and Ritts Jr., R. E. Leukocyte chemotaxis in diabetic patients and their nondiabetic first-degree relatives. Diabetes, 1976, 25: 880-883.
45. Andersen, B., Goldsmith, G. H., and Spagnvolo, P. J. Neutrophil adhesive dysfunction in diabetes mellitus: the role cellular plasma factors. J. Lab. Clin. Med., 1980, 111: 274-281
46. Wilson, R. M., Tomlinson, D. R., and Reeves, W. G. Neutrophil sorbitol production impairs oxidative killing in diabetes. Diabet. Med., 1987, 4: 37-40.
47. Davidson, N. J., Sowden, J. M., and Fletcher, J. Defective phagocytosis in insulin controlled diabetics: evidence for a reaction glucose and opsonizing proteins. J. Clin. Pathol., 1984, 37: 783-786.
48. 4 synthesis by polymorphonuclear leukocyte from male patients with diabetes mellitus. Prostaglandins Leukot. Med., 1984, 14: 305-311.
49. Speert, D. P., and Silva, J. R. Abnormalities of in vitro lymphocyte response to mitogen in diabetic children during acute ketoacidosis. Am. J. Dis. Child., 1978, 132: 1014-1017.
50. Kaye, W. A., Adri, M. N., Soelder, J. S., and others. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. N. Engl. J. Med., 1986, 315: 920-924.
51. Negishi, K., Gupta, S., Chandy, K. G., and others. Interferon responsive of natural killer cells in type I diabetic patients. Diabetes Res., 1988, 7: 49-52.
52. Vergani, D., Johnston, C., Abdullah, B., and Barnett, A. H. Low serum C4 concentration: an inherited predisposition to insulin dependent diabetes. B. M. J., 1983, 286: 923-928.
53. Sutherland, M. E., and Meyer, A. A. Necrotizing soft tissue infections. Surg. Clin. North Am., 1994, 74: 591-560.
54. Francis, K. R., Lamaute, H. R., Davis, J. M., and Pizzi, W. F. Implication of risk factors in necrotizing fasciitis. Am. Surg., 1993, 59: 304-308.
55. Parino, J. F., and Castro, D. Necrotizing lesions of soft tissue: a review. World J. Surg., 1991, 15: 235-239.
56. Goodson, W. H., and Hunt, T. K. Wound collagen accumulation in obese hyperglycemic mice. Diabetes, 1986, 35: 491-495.
57. Tengrup, I., Hallmans, G., and Agen, M. S. Granulation tissue formation and metabolism of zinc and copper in alloxan-diabetic rats. Scand. J. Plast. Reconstr. Surg. Hand Surg., 1988, 22: 41-45.
58. Yue, D. K., Swanson, B., Mclennan, S., and others. Abnormalities of granulation tissue and collagen formation in experimental diabetes, uremia, and malnutrition. Diabet. Med., 1986, 3: 221-225.
59. Walmsley, D., Wales, J. K., and Wiles, P. G. Reduced hyperglycemia following skin trauma: evidence for an impaired microvascular response to injury in the diabetic foot. Diabetologia, 1989, 32: 736-739.
60. Fahey, T. J. I., Sadaty, A., Jones III, W. J., and others. Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res., 1991, 50: 308-313.
61. Grontendorst, G. R., Martin, G. R., Pencer, D., and others. Stimulation of granulation tissue formation by platelet derived growth factor in normal and diabetic rats. J. Clin. Invest., 1985, 76: 2323-2329.
62. Taubol, R., and Rifkin, D. B. Recombinant basic fibroblast growth factor stimulates wound healing in wound healing-impaired db/db mice. J. Exp. Med., 1990, 172: 245-251.
63. Hennessey, P. J., Black, C. T., and Audressey, R. J. Epidermal growth factor and insulin act synergistically during diabetic healing. Arch. Surg., 1990, 125: 926-929.
64. Seyer-Hansen, M., Andreassen, T. T., Jorgensen, P. H., and Oxlund, H. Influence on biosynthetic human growth hormone on the biochemical strength development in skin incisional wounds on diabetic rats. Eur. Surg. Res., 1993, 25: 162-168.
65. Greene, D. A., Lattimer, S. A., and Sima, A. A. F. Sorbitol, phosphoinositides and sodium-potassium-AT-Pase in the pathogenesis of diabetic complications. N. Engl. J. Med., 1987, 316: 599-606.
66. Hawthorne, G. C., Bartlett, K., Hetherington, C. S., and Alberti, K. G. M. M. The effect of high glucose on the polyol pathway activity and myoinositol metabolism in cultured endothelial cells. Diabetologia, 1989, 32: 163-166.
67. Lorenzi, M., and Toledo, S. Myoinositol enhances the proliferation of human endothelial cells in culture but fails to prevent the delay induced by high glucose. Metabolism, 1986, 35: 824-829.
68. Barnett, P. A., Gonzalez, R. G., Chylack, L. T., and Chen, H.-M. The effect of oxidation on sorbitol pathway kinetics. Diabetes, 1986, 35: 426-432.
69. Wakasugi, M., Noguchi, T., Inoue, M., and others. Effect of aldose reductase inhibitors on prostacyclin synthesis by aortic ring from rats with streptozotocin-induced diabetes. Prostaglandins Leukot. Essent. Fatty Acids, 1991, 44: 233-236.
70. Tesfamariam, B., and Cohen, R. Role of sorbitol and myoinositol in the endothelial cells dysfunction caused by elevated glucose. Fed. Proc., 1990, 4: A867.
71. Shiba, T., Inoguchi, T., Sportman, J. R., and others. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol., 1993, 265: E783-E793.
72. Inoguchi, T., Batten, R., Handler, E., and others. Preferential elevation of protein kinase C isoform III and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. USA, 1992, 89: 11059-11063.
73. Ayo, S. H., Radnik, R., Garoni, J. A., and others. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell culture. Am. J. Physiol., 1991, 261: F571-F577.
74. Willams, B., and Schrier, R. W. Characterization of glucose-induced in situ protein kinase C activity in cultured vascular smooth muscle cells. Diabetes, 1993, 41: 1464-1472.
75. Berridge, M. J. Inositol triphosphate and diacylglycerol: two interacting second messengers. Ann. Rev. Biochem., 1987, 56: 159-193.
76. Dunlop, M., and Larkins, R. G. Pancreatic islet synthesize phospholipid de novo from glucose via acyldihydroxy acetone phosphate. Biochem. Biophys. Res. Commun., 1985, 132: 467-473.
77. Lee, T. S., Saltman, K. A., Ohashi, H., and King, G. L. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in diabetic vascular complications. Proc. Natl. Acad. Sci. USA, 1989, 86: 5141-5145.
78. Wolf, B. A., Williamson, J. R., Easom, R. A., and others. Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose. J. Clin. Invest., 1991, 87: 31-38.
79. Kunsaki, M., Bursell, S., Umeda, F., and others. Normalization of diacylglycerol-protein kinase C activation by vitamin E in aorta of diabetic rats and cultured rat smooth muscle cells exposed to elevated glucose. Diabetes, 1994, 43: 1372-1377.
80. Vlassara, H., Bucala, R., and Striker, L. Pathogenesis effect of advanced glycosylation: biochemical and biologic implication for diabetes and aging. Lab. Invest., 1994, 70: 138-151.
81. Schmit, A.-M., Vianna, M., Gerlach, M., and others. Isolation and characterization of binding protein for advanced glycosylation end products from lung tissue which are present on the endothelial cells surface. J. Biol. Chem., 1992, 267: 14987-14997.
82. Vlassara, H., Brownlee, M., and Cerami, A. Novel macrophage receptor for glucose-modified protein is distinct from previously described scavenger receptors. J. Exp. Med., 1986, 164: 1301-1309.
83. Skolnik, E. Y., Yang, Z., Makita, Z., and others. Human and rat mesangial cell receptor for glucose modified protein: a potential role in kidney tissue remodeling and diabetic nephropathy. J. Exp. Med., 1991, 174: 931-939.
84. Brett, J., Schmitt, A. M., Zou, Y. S., and others. Tissue distribution of the receptor for advanced glycosylation end products (RAGE): expression in smooth muscle, cardiac myocyte and neural tissue in addition to vascular tissue. Am. J. Pathol., 1993, 143: 1699-1712.
85. Esposito, C., Gerlach, H., Brett, J., and others. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J. Exp. Med., 1989, 170: 1387-1407.
86. Yan, S.-D., Schmidt, A.-M., Anderson, G. M., and others. Enhanced cellular oxidant stress by the interaction of advanced glycosylation end products with their receptors/binding proteins. J. Biol. Chem., 1994, 269: 9889-9897.
87. Collins, T. Endothelial nuclear factor-kB and initiation of atherosclerosis. Lab. Invest., 1993, 68: 499-508.
88. Schmidt, A.-M., Zhang, J. H., Grundall, J., and others. Interaction of advanced glycosylation end products with their endothelial cell receptor leads to enhanced expression of VCAM-I: a mechanism for augmented monocyte-vessel wall interaction in diabetes. F. A. S. E. B. J., 1994, 8: 3841.
89. Kirsten, M., Brett, J., Radoff, S., and others. Advanced glycosylation induces the transendothelial human monocyte chemotaxis and secretion of PDGF: role in vascular disease in diabetes and aging. Proc. Natl. Acad. Sci. USA, 1990, 87: 9010-9014.
90. Vlassara, H., Brownlee, M., Manogue, K. R., and others. Cachectin/TNF and IL-I induced by glucose modified proteins: role in normal tissue remodeling. Science, 1988, 240: 1546-1548.
91. Iberg, N., and Fluckiger, R. Non-enzymatic glycosylation of albumin in vivo. J. Biol. Chem., 1986, 261: 13542-13545
92. Kent, M. J. C., Light, N. D., and Bailey, A. J. Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation. Biochem. J., 1985, 225: 745-752.
93. Lubec, G., and Pollak, A. Reduced susceptibility of non enzymatically glucosylated glomerular basement membrane to protease: is thickening of glomerular membrane due to reduced proteolytic degradation? Renal Physiol., 1980, 3: 4-8.
94. Brownlee, M., Vlassara, H., and Cerami, A. Non enzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes, 1985, 34: 938-941.
95. Brownlee, M., Ponger, S., and Cerami, A. Covalent attachment of soluble protein by non enzymatically glycosylated collagen: a role in the in situ formation of immune complex. J. Exp. Med., 1983, 158: 1739.
96. Hammes, H.-P., Martin, S., Federlin, K., and others. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. USA, 1991, 88: 11555-11558.
97. Soulis-Liparota, T., Cooper, M., Papazoglou, D., and others. Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozotocin-induced diabetic rats. Diabetes, 1991, 40: 1328-1334.
98. Wolff, S. P. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br. Med. Bull., 1993, 49: 642-652.
99. Guigliano, D., Ceriello, A., and Paolisso, G. Diabetes mellitus, hypertension and cardiovascular disease: which role for oxidative stress? Metabolism, 1995. 44: 363-368.
100. Katoh, K. Possible relevance of lipid peroxidation and thromboxane production to the initiation and/or microangiopathy in non-hyperlipidemic type 2 diabetes mellitus. Diabet. Res. Clin. Pract., 1992, 18: 89-98.
101. Pyorala, K., Laasko, M., and Uusitupa, M. Diabetes and atherosclerosis: an epidemiologic view. Diabet. Metab. Rev., 1987, 3: 463-524.
102. Jarret, R. J. Cardiovascular disease and hypertension in diabetes mellitus. Diabet. Metab. Rev., 1989, 5: 547-558.
103. Barret-Connor, E., and Khow, K. T. Diabetes mellitus: an independent risk factor for stroke? Am. J. Epidemiol., 1988, 128: 116-123.
104. Kim, D. K., Escalante, D. A., and Garber, A. J. Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism. Clin. Ther., 1993, 15: 766-778.
105. Lewis, G. F., O'Meara, Soltys, P. A., and others. Fasting hypertriglyceridemia in non-insulin-dependent diabetes mellitus is important predictor of postprandial lipid and lipoprotein abnormalities. J. Clin. Endocrinol. Metab., 1991, 72: 934-944.
106. Taskinen, M.-R., Kuusi, T., Helve, E., and others. Insulin therapy induces antiatherogenic changes of serum lipoproteins in non-insulin-dependent diabetes. Arteriosclerosis, 1988, 8: 168-177.
107. Bagdade, J. D., Buchanan, W. E., Kuusi, T., and others. Persistent abnormalities in lipoprotein composition in non-insulin-dependent diabetes after intensive insulin therapy. Arteriosclerosis, 1990, 10: 232-239.
108. Barakat, H. A., Carpenter, J. W., Mclenden, V. D., and others. Influence of obesity, impaired glucose tolerance and NIDDM on LDL structure and composition: possible link between hyperinsulinemia and atherosclerosis. Diabetes, 1990, 39: 1527-1533.
109. Chriestlieb, A. R., Warram, J. M., Krolewski, A. S., and others. Hypertension, the major risk factor in juvenile-onset insulin dependent diabetes. Diabetes, 1981, 30: 90-96.
110. Brazilay, J., Warram, J. H., Bak, M., and others. Predisposition to hypertension: a risk factor for nephropathy and hypertension. Kidney Int., 1992, 41: 723-730.
111. West, K. M., Ahuja, M. M. S., Bennett, P. H., and others. The role of circulating glucose and triglyceride concentration and their interaction with other "risk factors" as determinants of arterial disease in nine population samples from WHO Multinational Study. Diabetes Care, 1983, 6: 361-369.
112. Morrish, N. J., Stevens, L. K., Head, J., and others. A prospective study of mortality among middle-aged diabetic patients. (The London cohort of the WHO Multinational Study of Vascular Disease in diabetics II: associated risk factors). Diabetologia, 1990, 33: 542-548.
113. Fontbonne, A., Charles, M. A., Thibult, N., and others. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population. The Paris prospective study, 15-year follow-up. Diabetologia, 1991, 34: 356-361.
114. Modan, M., Or, J., Karasik, A., and others. Hyperinsulinemia, sex, and risk of atherosclerotic cardiovascular disease. Circulation, 1991, 84: 1165-1175.
115. Ferrara, A., Barret-Connor, E., and Edelstein, S. L. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: The Rancho Bernardo Study, 1984 to 1991. Am. J. Epidemiol., 1994, 140: 857-869.
116. Ferranini, E., Haffner, S. M., Mitchell, B. D., and others. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia, 1991, 34: 416-422.
117. LeCroix, A. Z., Lang, J., Scherr, P., and others. Smoking and mortality among older men and women in three populations. N. Engl. J. Med., 1991, 324: 1619-1625.
118. Palumbo, P. J., O'Fallen, W. M., Osmundson, P. J., and others. Progression of peripheral occlusive arterial disease in diabetes mellitus. What factors are predictive? Arch. Intern. Med., 1991, 151: 717-721.
119. Blann, A. D., and McCollum, C. N. Adverse influence of cigarette smoking on the endothelium. Thromb. Haemost., 1993, 70: 707-711.
120. Kimura, S., Nishhinaga, M., Ozawa, T., and others. Thrombin generation as an acute effect of cigarette smoking. Am. Heart J., 1994, 128: 7-11.
121. Freeman, D. J., Griffin, B. A., Murray, E., and others. Smoking and plasma lipoproteins in man: effects on low density lipoprotein cholesterol levels and high density lipoprotein subfraction distribution. Eur. J. Clin. Invest., 1993, 23: 630-640.
122. Ross, R. Mechanism of atherosclerosis: a review. Adv. Nephrol., 1990, 19: 79-86.
123. Clinton, K., and Libby, P. Cytokinins and growth factors in atherogenesis. Arch. Pathol. Lab. Med., 1992, 116: 1292-1300.
124. Ginsberg, H. N. Lipoprotein physiology in non diabetic and diabetic states. Relationship to atherogenesis. Diabetes Care., 1991, 14: 839-855.
125. Lopes-Virella, M. F., Klein, R. L., Lyon, T. J., and others. Glycosylation of low density lipoprotein enhances cholestryl ester synthesis in human monocytederived macrophage. Diabetes, 1988, 37: 550-557.
126. Witzum, J. L., Fisher, M., Pietro, T., and others. Non enzymatic glycosylation of high density lipoprotein accelerates its catabolism in guinea pigs. Diabetes, 1982, 31: 1029-1032.
127. Duell, P. B., Oram, J. F., and Beirman, E. L. Non enzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes, 1991, 40: 377-384.
128. Cushing, S. D., Berliner, J. A., Valente, A. J., and others. Minimal modified low density lipoprotein induces monocyte chemotactic protein I in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA, 1987, 84: 2995-2958.
129. Berliner, J. A., Territo, M. C., Sevanian, A., and others. Minimally modified low density lipoprotein stimulate monocyte-endothelial interactions. J. Clin. Invest., 1990, 85: 1260-1266.
130. Drake, T. A., Hannani, K., Fei, H. H., and others. Minimally oxidized LDL induces tissue factor expression in cultured human endothelial cells. Am. J. Pathol., 1991, 138: 601-607.
131. Baynes, J. W. Role of oxidative stress in development of complications in diabetes. Diabetes, 1991, 40: 405-412.
132. Witztum, J. L., Steinbrecher, U. P., Kesaniemi, Y. A., and others. Autoantibody to glycosylated protein in the plasma of patient with diabetes mellitus. Proc. Natl. Acad. Sci. USA, 1984, 81: 3204-3208.
133. Lopes-Virella, M., and Virella, G. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes, 1992, 41: 86-91.
134. Gisinger, C., Virella, G. T., and Lopes-Virella, M. Erythrocyte-bound low density lipoprotein (LDL) immune complex leads to cholestryl ester accumulation in human monocyte derived macrophage. Clin. Immunol. Immunopathol., 1991, 59: 37-52.
135. Virella, G., Munoz, J. F., and Galbraith, G. M. Activation of human monocyte-derived macrophage by immune complex containing low density lipoprotein. Clin. Immunol. Immunopathol., 1995, 75: 179-189.
136. Somlyo, A. P., and Somlyo, A. V. Signal transduction and regulation in smooth muscle. Nature, 1994, 327: 231-236.
137. Natarajan, R., Gonzalez, N., Xu, L., and Nadler, J. L. Vascular smooth muscle cell exhibit increased growth in response to elevated glucose. Biochem. Biophys. Res. Commun., 1992, 187: 552-560.
138. Alipui, C., Ramos, K., and Tenner Jr., T. E. Alteration of rabbit aortic smooth muscle cell proliferation in diabetes mellitus. Cardiovasc. Res., 1993, 27: 1229-1232.
139. Pfeifle, B., and Ditschuneit, H. Two separate receptors for insulin and insulin-like growth factors on arterial smooth muscle cells. Exp. Clin. Endocrinol., 1983, 81: 280-286.
140. Bornfeldt, K. E., Arnqvist, H. J., and Capron, L. In vivo proliferation of rat vascular smooth muscle in relation to diabetes mellitus, insulin-like growth factor-I and insulin. Diabetologia, 1992, 35: 104-108.
141. Weidmann, P., Beretta-Piccoli, C., and Trost, B. N. Pressor factors and responsiveness in hypertension accompanying diabetes mellitus. Hypertension, 1985, 7: II33-II42.
142. Drury, P. L., Smith, G. M., and Ferris, J. B. Increased vasopressor responsiveness to angiotensin II in type I (insulin-dependent) diabetic patient without complications. Diabetologia, 1983, 27: 174-179.
143. Vierhapper, H. Effect of exogenous insulin on blood pressure regulation in healthy diabetic subjects. Hypertension, 1985, 7: II49-II53.
144. Yagi, S., Takata, S., and Kiyokawa, H. Effect of insulin on vasoconstrictive response to norepinephrine and angiotensin II in rabbits femoral artery and vein. Diabetes, 1988, 37: 1064-1067.
145. Standley, P. R., Zhang, F., Ram, J. L., and others. Insulin attenuates vasopressin induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. J. Clin. Invest., 1991, 88: 1230-1236.
146. Hori, M., Saito, F., Fittengoff, M., and others. Insulin attenuate angiotensin II mediated calcium mobilization in cultured rat vascular smooth muscle by depletion of intracellular calcium stores. Clin. Res., 1991, 39: 88A.
147. Tesfamariam, B., Brown, M. L., Deykin, D., and Cohen, R. A. Elevated glucose promotes generation of endothelial-derived vasoconstrictor prostanoid in rabbit aorta. J. Clin. Invest., 1990, 85: 929-932.
148. Tesfamariam, B., Brown, M. L., and Cohen, R. A. Elevated glucose impairs the endothelium-dependent relaxation by activating protein kinase C. J. Clin. Invest., 1991, 87: 1643-1648.
149. 2. Am. J. Physiol., 1989, 26: H1327-H1333.
150. Takahashi, K., Ghatei, M. A., Lam, H.-C., and others. Elevated plasma endothelin in patient with diabetes mellitus. Diabetologia, 1990, 33: 306-310.
151. Yamauchi, T., Ohnaka, K., Takayanagi, R., and others. Enhanced secretion of endothelin-I by elevated glucose levels from cultured bovine aortic endothelial cells. F. E. B. S. Lett., 1990, 267: 16-18.
152. Hu, R.-M., Levin, E. R., Pedram, A., and Frank, H. J. L. Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes, 1993, 42: 351-358.
153. Oliver, F. J., LaRubia, G., Feener, E. P., and others. Stimulation of endothelin-I gene expression by insulin in endothelial cells. J. Biol. Chem., 1991, 266: 23251-23256.
154. Moncada, S., and Higgs, A. The L-arginine-nitric oxide pathway. N. Engl. J. Med., 1993, 329: 2002-2012.
155. Wennmalm, A. Endothelial nitric oxide and cardiovascular disease. J. Intern. Med., 1994, 235: 317-327.
156. Scherrer, U., Randin, D., Vollenweider, P., and others. Nitric oxide release accounts for insulin's vascular effect in human. J. Clin. Invest., 1994, 94: 2511-2515.
157. Schini, V. B., Catovsky, S., Schray-Utz, B., and others. Insulin-like growth factor I inhibits induction of nitric oxide synthetase in vascular smooth muscle cells. Circ. Res., 1994, 74: 24-32.
158. Bucala, R., Tracey, K. J., and Cerami, A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest., 1991, 87: 432-438.
159. Corbett, J. A., Tilton, R. G., Chang, K., and others. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes, 1992, 41: 552-556.
160. Lorenzi, M., Cagleiro, E., and Toledo, S. Glucose toxicity for human endothelial cells in culture. Diabetes, 1985, 34: 621-627.
161. Kamal, K., Mills, I., and Sumpio, B. E. Proliferation of immortalized human dermal microvascular endothelial cells is inhibited by elevated glucose. F. A. S. E. B. J., 1995, 9: A872.
162. Sharma, N. K., Gardiner, T. A., and Archer, D. B. A morphologic and autoradiograhic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. Am. J. Ophtholmol., 1985, 100: 51-60.
163. Lorenzi, M., Monstisano, D. F., Toledo, S., and Barrieux, A. High glucose induce DNA damage in cultured human endothelial cells. J. Clin. Invest., 1986, 77: 322-325.
164. Cagliero, E., Roth, T., Roys, S., and Lorenzi, M. Characteristics and mechanisms of high glucose induced over expression of basement membrane component in cultured human endothelial cells. Diabetes, 1991, 40: 102-110.
165. Roy, S., and Lorenzi, M. The memory of abnormal gene expression induced by high glucose in human endothelial cells is gene specific. Diabetes, 1991, 40: 9A.
166. Mascardo, R. N. The effect of hyperglycemia on the directed migration of wounded endothelial cell monolayer. Metabolism, 1988, 37: 102-110.
167. Jilal, I., Crettaz, M., Hachiya, H. L., and others. Characterization of the receptors for insulin and insulin-like growth factors on micro- and macrovascular tissue. Endocrinology, 1985, 117: 1222-1229.
168. Kwok, C. F., Goldstein, B. J., Muller-Weiland, D., and others. Identification of persistent defects in insulin receptor structure and function in capillary endothelial cells from diabetic rats. J. Clin. Invest., 1989, 83: 127-136.
169. Wallum, B. J., Taborsky Jr., G. J., and Porte Jr., D. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J. Clin. Invest., 1987, 64: 190-194.
170. King, G. L., Goodman, A. D., Bunzey, S., and others. Receptors and growth-promoting effect of insulin and insulin-like growth factor on cells from bovine retinal capillaries and aorta. J. Clin. Invest., 1985, 75: 1028-1036.
171. Sages, H. Collagens of basement membranes. J. Invest. Dermatol., 1982, 79: 51S-59S.
172. Faucet, D. W. A Textbook of Histology. 12th ed. New York: Chapman & Hall, 1994.
173. Mohan, P. S., and Spiro, R. G. Macromolecular organization on basement membranes. J. Biol. Chem., 1986, 261: 4328-4336.
174. William, J. R., Tilton, R. G., Chang, K., and Kilo, C. membrane abnormalities in diabetes mellitus: Relationship to clinical microangiopathy. Diabet. Metab. Rev., 1988, 4: 339-370.
175. Dornan, T. L., and Tartersall, R. B. Muscle capillary basement membrane thickening: marker of microvascular complication or false prophet. Diabet. Med., 1986, 3: 413-418.
176. Boyd, R. B., Burke, J. P., Thompson, V. W., and Nugent, J. F. Significance of capillary basement membrane changes in diabetes mellitus. J. Am. Podiatr. Med. Assoc., 1990, 80: 307-313.
177. Vernier, R. L., Steffes, M. W., Sisson-Ross, S., and Mauer, S. M. Heparan sulfate proteoglycan in the glomerular basement membrane in type I diabetes mellitus. Kidney Int., 1992, 41: 1070-1080.
178. Shimomura, H., and Spiro, R. G. Studies on macromolecular component of human glomerular basement membrane and alteration in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes, 1987, 36: 374-381.
179. Ziyadeh, F. N. Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int., 1993, 43: 114-120.
180. Rasmussen, L. M., and Ledet, T. Aortic collagen alteration in human diabetes mellitus. Changes in basement membrane collagen content and susceptibility to total collagen to cyanogen bromide solubilization. Diabetologia, 1993, 36: 445-453.
181. Brownlee, M., Cerami, A., and Vlassara, H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med., 1988, 318: 1315-1321.
182. Ellis, E. N., and Good, B. H. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism, 1991, 40: 1016-1019.
183. Engerman, R. L., Kern, T. S., and Garment, M. B. Capillary basement membrane in retina, kidney and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition. J. Diabetes Complications, 1993, 7: 241-245.
184. Ayo, S. H., Radnick, R. A., Glass, W. F., and others. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high glucose medium. Am. J. Physiol., 1991, 260: F185-F191.
185. Ayo, S. H., Radick, R., Garoni, J., and others. High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell culture. Am. J. Physiol., 1991, 261: F571-F577.
186. Tomono, S., Kawazu, S., Kato, N., and others. Clinical implication of serum levels of basement membrane component in diabetic patients with and without albuminuria. J. Diabetes Complications, 1991, 5: 193-194.
187. 1) are increased in sera of diabetic and activate platelet in vitro. Haemostasis, 1986, 16: 428-432.
188. Cunha-Vaz, J., De Abreu, J. R. E., Compos, A. J., and Figo, G. M. Early breakdown of the blood-brain barrier in diabetes. Br. J. Ophthalmol., 1975, 59: 649-656.
189. Mogenesen, C. E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N. Engl. J. Med., 1984, 310: 356-360.
190. Yamaji, T., Fukuhara, T., and Kinoshita, M. Increased capillary permeability to albuminuria in diabetic rat myocardium. Circ. Res., 1993, 72: 947-957.
191. Kubota, I., Fukuhara, T., and Kinoshita, M. Permeability of small coronary arteries and myocardial injury in hypertensive diabetic rats. Int. J. Cardiol., 1990, 29: 349-355.
192. White, N. H., Waltman, S. R., Krupin, T., and others. Reversal of abnormalities in ocular fluorophotometry in insulin-dependent diabetes after five to nine months of improved metabolic control. Diabetes, 1982, 31: 80-85.
193. Chakrabarti, S., Prasher, S., and Sima, A. A. Augmented polyol pathway activity and retinal pigmented epithelial permeability in the diabetic BB rats. Diabetes Res. Clin. Pract., 1990, 8: 1-11.
194. Williamson, J. R., Chang, K., Rowold, E., and others. Sorbinil prevents diabetes-induced increases in vascular permeability but does not alter collagen cross-linking. Diabetes, 1985, 34: 703-705.
195. Daniels, B. S., and Hauser, E. B. Glycosylation of albumin, not glomerular basement membrane, alter permeability in an in vitro model. Diabetes, 1992, 41: 1415-1421.
196. Vlassara, H., Fuh, H., Makita, Z., and others. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complication. Proc. Natl. Acad. Sci. USA, 1992, 89: 12043-12047.
197. Tooke, J. E. Microvascular hemodynamics in diabetes mellitus. Clin. Sci., 1986, 70: 119-125.
198. Parving, H.-H., Viberti, G. C., Keen, H., and others. Hemodynamic factor in the genesis of diabetic microangiopathy. Metab. Clin. Exp., 1983, 32: 943-949.
199. Pazos-Moura, C. C., Moura, E. G., and others. Nailfold capillaroscopy in non-insulin-dependent diabetes mellitus: blood flow velocity during rest and post occlusive reactive hyperaemia. Clin. Physiol., 1990, 10: 451-461.
200. Parving, H.-H., Kastrup, H., Smidt, U. M., and others. Impaired autoregulation of glomerular filtration rate in type I (insulin-dependent) diabetic patients with nephropathy. Diabetologia, 1984, 27: 247-252.
201. Sandeman, D. D., Shore, A. C., and Tooke, J. E. Relation of skin capillary pressure in patients with insulin-dependent diabetes mellitus to complications and metabolic control. N. Engl. J. Med., 1992, 327: 760-764.
202. Tooke, J. E., Sandeman, D. D., and Shore, A. C. Microvascular hemodynamics in hypertension and diabetes. J. Cardiovasc. Pharmacol., 1991, 18: S51-S53.
203. Lowe, G. D. O. Blood viscosity and cardiovascular disease. Thromb. Haemost., 1992, 67: 494-498.
204. Fowkes, F. G. R., Pell, J. P., Donan, P. T., and others. Sex difference in susceptibility to etiologic factors for peripheral atherosclerosis: importance of plasma fibrinogen and blood viscosity. Arterioscler. Thromb., 1991, 14: 862-868.
205. Smith, W. C., Lowe, G. D. O., Lee, A. J., and Tunstall-Pedoe, H. Rheological determinant of blood pressure in a Scottish adult population. J. Hypertens., 1992, 10: 467-472.
206. Lowe, G. D. O., Fowkes, F. G. R., Dawes, J., and others. Blood viscosity, fibrinogen, and activation of coagulation and leukocyte in peripheral arterial disease and the normal population in the Edinburgh Artery Disease. Circulation, 1993, 87: 1915-1920.
207. Memeh, C. U. Difference between plasma viscosity and protein of type I and type II diabetic Africans in early phase of diabetes. Horm. Metab. Res., 1993, 25: 21-23.
208. Zioupos, P., Barbenel, J. C., Lowe, G. D. O., and MacRury, S. Foot microcirculation and blood rheology in diabetes. J. Biomed. Eng., 1993, 15: 155-158.
209. Brown, C. D., Zhao, Z.-H., Berweck, S., and others. Effect of Alloxan-induced diabetes in hemorheology in rabbits. Horm. Metab. Res., 1992, 24: 254-257.
210. Schut, N. H., Van Arkel, E. C., Hardeman, M. R., and others. Blood and plasma viscosity in diabetes: possible contribution to late organ complications? Diabetes Res., 1992, 19: 31-35.
211. McMillian, D. E. Plasma protein changes, blood viscosity and diabetic micro-angiopathy. Diabetes, 1976, 25: 858-864.
212. Reid, H. L., and Memeh, C. U. Abnormal serum protein profile in African diabetics. Med. Sci. Res., 1990, 18: 321-322.
213. MacRury, S. M., and Lowe, G. D. O. Blood rheology in diabetes mellitus. Diabet. Med., 1990, 7: 285-291.
214. McMillian, D. E., Utterback, N. G., and LaPuma, J. Reduced erythrocyte deformability in diabetes. Diabetes, 1978, 27: 895-901.
215. MacRury, S. M., Small, M., Andersen, J., and others. Evaluation of red cell deformability by a filtration method in type I and type II diabetes with and without vascular complications. Diabetes Res., 1990, 13: 61-65.
216. Le Devehat, C., Vimeux, M., Bondoux, G., and Khodabandehlov, T. Red aggregation in diabetes mellitus. Int. Angiol., 1990, 9: 11-15.
217. Ziegler, O., Guerci, B., Muller, S., and others. Increased erythrocyte aggregation in insulin-dependent diabetes mellitus and its relationship to plasma factors: a multivariate analysis. Metabolism, 1994, 43: 1182-1186.
218. Watala, C. Hyperglycemia alters the physio-chemical properties of proteins in erythrocyte membrane in diabetic patients. Int. J. Biochem., 1992, 24: 1755-1761.
219. Roger, M. E., Williams, D. T., Niththyananthan, R., and others. Decrease in erythrocyte glycophorin sialic acid content is associated with increased aggregation in human diabetes. Clin. Sci., 1992, 82: 309-313.
220. Murakami, K., Kondo, T., Ohtsuka, Y., and others. Impairment of glutathione metabolism in erythrocyte from patients with diabetes mellitus. Metabolism, 1989, 38: 753-758.
221. Stern, D. M., Esposito, C., Gerlach, H., and others. Endothelium and regulation of coagulation. Diabetes Care, 1991, 14: 160-166.
222. Ono, H., Umeda, F., Inoguchi, T., and Ibayashi, H. Glucose inhibits the prostacyclin production by cultured aortic endothelial cells. Thromb. Haemost., 1988, 60: 174-177.
223. Boeri, D., Almus, F. E., Maiello, M., and others. Modification of tissue-factor mRNA and protein response to thrombin and interleukin-I by high glucose in cultured human endothelial growth. Diabetes, 1989, 38: 212-218.
224. Porta, M., LeSelva, M., and Molinatti, P. A. Von Willebrand factor and endothelial abnormalities in diabetic microangiopathy. Diabetes Care, 1991, 14: 167-172.
225. Ganda, O. P., and Arkin, C. F. Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care, 1992, 15: 1245-1250.
226. Ceriello, A., Giugliano, D., Quatraro, A., and others. Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia, 1988, 31: 889-891.
227. Khawand, C. E., Jamart, J., Doonckier, J., and others. Hemostasis variable in type I diabetic patient without demonstrable vascular complication. Diabetes Care, 1993, 16: 1137-1145.
228. Ostermann, H., and Vandeloo, J. Factors of hemostatic system in diabetic patient: a survey of controlled studies. Haemostasis, 1986, 16: 386-416.
229. DeFeo, P., Gaisano, M. G., and Haymond, M. W. Differential effect of insulin deficiency on albumin and fibrinogen synthesis in humans. J. Clin. Invest., 1991, 88: 833-840.
230. Ceriello, A., Giugliano, D., Quatraro, A., and others. Daily rapid blood glucose variation may condition antithrombin III biological activity but not its plasma concentration in insulin-dependent diabetes. Diabetes Metab., 1987, 13: 16-19.
231. Ceriello, A., Giugliano, D., Quatraro, A., and others. Evidence for a hyperglycemia-dependent decrease of antithrombin III-thrombin complex formation in human. Diabetologia, 1990, 33: 163-167.
232. Ceriello, A., Quatraro, A., Della Russo, P., and others. Protein C deficiency in insulin-dependent diabetes: a hyperglycemia-related phenomenon. Thromb. Haemost., 1990, 64: 104-107.
233. Gough, S. C. L., and Grant, P. J. The fibrinolytic system in diabetes mellitus. Diabet. Med., 1991, 8: 898-905.
234. Walmsley, D., Hampton, K. K., and Grant, P. J. Contrasting fibrinolytic responses in type I (insulin-dependent) and type II (non-insulin-dependent) diabetes. Diabet. Med., 1991, 8: 954-959.
235. Stiko-Rahm, A., Wiman, B., Hamsten, and Nilsson, J. Secretion of plasminogen activator inhibitor I from cultured umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis, 1990, 10: 1067-1073.
236. Davis, J. W., Hartman, C. R., Davis, R. F., and others. Platelet aggregate ratio in diabetes mellitus. Acta Haematol., 1982, 67: 222-224.
237. Winocour, P. D. The role of platelets in the pathogenesis of diabetic vascular disease. In: Complications of Diabetes Mellitus. Edited by B. Draznin, S. Melmed, and D. LeRoith, Pp. 37-42. New York: Alan R. Liss Inc., 1989.
238. Winocour, P. D., Perry, D. W., and Kinlough-Rathbone, R. L. Hypersensitivity to ADP of platelets from diabetic rats associated with enhanced fibrinogen binding. Eur. J. Clin. Invest., 1992, 22: 19-23.
239. Winocour, P. D., Halushka, P. V., and Colwell, J. A. Platelet involvement in diabetes mellitus. In: The Platelet: Physiology and Pharmacology. Edited by G. L. Longenecker. Pp. 341-66. New York: Academic Press, 1985.
240. Tschoepe, D., Roesen, P., Schwippert, B., and Gries, F. A. Platelets in diabetes: the role in hemostatic regulation in atherosclerosis. Semin. Thromb. Hemost., 1993, 19: 122-128.
241. Villanueva, G. B., and Allen, N. Demonstration of altered antithrombin III activity due to non enzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients. Diabetes, 1988, 37: 1103-1107.
242. Ceriello, A., Marchi, E., Barbanti, M., and others. Non-enzymatic glycosylation reduces heparin cofactor II antithrombin activity. Diabetologia, 1990, 33: 205-207.
243. Watala, C., Winocour, P. D., Kinlough-Rathbone, R. L., and others. Relationship among membrane fluidity, glycosylation of protein and cholesterol to phospholipid (C/P) molar ratio in platelet membrane from diabetic and control subjects. F. A. S. E. B. J., 1990, 4: A1029.
244. Cohen, I., Burk, D., Fullerton, R. J., and others. Non enzymatic glycation of human blood platelet proteins. Thromb. Res., 1989, 55: 341-349.
245. Collier, A., Rumley, A. G., Patterson, J. R., and others. Free radical activity and hemostatic factor in NIDDM patients with and without microalbuminuria. Diabetes, 1992, 41: 909-913.
246. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med., 1993, 329: 977-986.
247. Reach, G. Continuous glucose monitoring with a subcutaneous sensor: rationale, requirement and achievement, and prospects. In: The Diabetes Annual. Edited by S. M. Marshall, P. D. Homes, K. G. M. M. Alberti, and L. P. Krall. 7th ed., pp. 332-48. Amsterdam: Elsevier Sci BV, 1993.
248. Pickup, J. Glucose sensors and closed-loop insulin delivery. In: Biotechnology of Insulin Therapy. Edited by J. Pickup. Pp. 126-53. Oxford: Blackwell Scientific, 1991.
249. Zier, H., Kerner, W., Bruckel, J., and Pfeiffer, E. Glucosensor Unitec Ulm: a portable continuously measuring glucose sensor and monitor. Biomed Tech., 1990, 35: 2-4.
250. Salem, J., and Charles, M. A. Devices for insulin administration. Diabetes Care, 1990, 13: 955-979.
251. Illum, L., and Davis, S. S. Intranasal insulin: clinical pharmacokinetics. Clin. Pharmacokinet., 1992, 23: 30-41.
252. Kennedy, F. B. Recent developments in insulin delivery techniques: current status and future potential. Drugs., 1991, 42: 213-227.
253. Tachibana, K., and Tachibana, S. Transdermal delivery of insulin by ultrasonic vibration. J. Pharm. Pharmacol., 1991, 43: 270-271.
254. Wredling, R., Liu, D., Lins, P. E., and Adamson, U. Variation of insulin absorption during subcutaneous and peritoneal infusion in insulin-dependent diabetic patients with unsatisfactory long-term glycemic response to continuous subcutaneous insulin therapy. Diabet. Metab., 1991, 17: 456-459.
255. Duckworth, W. C., Saudek, C. D., and Henry, R. R. Why intraperitoneal delivery of insulin with implantable pumps in NIDDM? Diabetes, 1992, 41: 657-661.
256. Sutherland, D. E. R. Pancreatic transplantation: an update. Diabetes Metab. Rev., 1993, 1: 152-165.
257. Morel, P., Chau, C., Brayman, K., and others. Quality of metabolic control at 2 to 12 years after a pancreas transplant. Transplant. Proc., 1992, 24: 835-838.
258. Scheider, A., Meyer-Schwickerath, E., Nusser, J., and others. Diabetic retinopathy and pancreas transplantation: a 3-year follow-up. Diabetologia, 1991, 34: 95-99.
259. Muller-Felber, W., Langgraf, R., Wagner, S. T., and others. Follow-up study of sensory-motor polyneuropathy in type I (insulin-dependent) diabetic subjects after simultaneous pancreas and kidney transplantation and after graft rejection. Diabetologia, 1991, 34: 113-117.
260. Abendroth, D., Schmand, J., Langraf, R., and others. Diabetic microangiopathy in type I (insulin-dependent) diabetic patients after successful pancreatic and kidney or solitary kidney transplantation. Diabetologia, 1991, 34: 131-134.
261. Stratta, R. J., Taylor, R. J., Bynon, J. S., and others. Surgical treatment of diabetes mellitus with pancreatic transplantation. Ann. Surg., 1994, 220: 809-817.
262. Pipeleers, D., Keymeulen, B., and Korburt, G. Islet transplantation. In: The Diabetes Annual. Edited by S. M. Marhall, and P. D. Home. 8th ed., pp. 299-330. Amsterdam: Elsevier Science BV, 1994.